Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection for domestic production [1] Group 1: Product Information - Fuxin Qibai monoclonal antibody is a fully human anti-IL-1β monoclonal antibody that specifically blocks the binding of IL-1β to its receptor, thereby inhibiting the activation of downstream signaling pathways [1] - The drug is primarily used for the treatment of non-infectious uveitis, and there are currently no similar drugs approved for the same disease area in both domestic and international markets [1]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received a notice of acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection, which is intended for the treatment of non-infectious uveitis [1] Group 1 - The clinical trial application for Fuxin Qibai monoclonal antibody has been accepted, indicating progress in the drug development process [1] - Fuxin Qibai is a fully human anti-IL-1β monoclonal antibody developed by Changchun Jinsai Pharmaceutical, designed to specifically block the binding of IL-1β to its receptor IL-1R [1] - Currently, there are no similar drugs approved for the same disease area in both domestic and international markets, highlighting a potential market opportunity for the company [1]